An Open-label, Multicohort Phase I/II Study of the Cadonilimab (AK104) Combination Regimen as First-line Treatment for HER2-expressing, Unresectable Locally Advanced or Metastatic Gastric (G) or Gastroesophageal Junction (GEJ) Cancer
Latest Information Update: 24 Oct 2024
At a glance
- Drugs Cadonilimab (Primary) ; Capecitabine (Primary) ; Disitamab vedotin (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Oxaliplatin (Primary) ; Trastuzumab (Primary)
- Indications Gastric cancer; Oesophageal cancer
- Focus Pharmacokinetics; Therapeutic Use
- 24 Oct 2024 New trial record